Opdivo receives EC approval in Esophageal/GEJ indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Commission has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. 

Opdivo is sponsored by Bristol Myers Squibb. 

Approval is based on phase III results from the CheckMate -577 trial. Opdivo is now the first and only approved adjuvant therapeutic option in the European Union.

Opdivo also received approval from FDA in May 2021 for the adjuvant treatment of completely resected esophageal or GEJ cancer with residual pathologic disease in patients who have received CRT.

Table of Contents

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login